Boston Scientific/$BSX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Ticker
$BSX
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Employees
53,000
ISIN
US1011371077
Website
BSX Metrics
BasicAdvanced
$153B
75.62
$1.37
0.69
-
Price and volume
Market cap
$153B
Beta
0.69
52-week high
$107.53
52-week low
$71.88
Average daily volume
7.9M
Financial strength
Current ratio
1.45
Quick ratio
0.676
Long term debt to equity
48.701
Total debt to equity
51.029
Interest coverage (TTM)
10.45%
Profitability
EBITDA (TTM)
4,606.25
Gross margin (TTM)
68.45%
Net profit margin (TTM)
11.58%
Operating margin (TTM)
18.94%
Effective tax rate (TTM)
18.32%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
5.28%
Return on equity (TTM)
9.50%
Valuation
Price to earnings (TTM)
75.616
Price to revenue (TTM)
8.7
Price to book
6.9
Price to tangible book (TTM)
-76.29
Price to free cash flow (TTM)
50.336
Free cash flow yield (TTM)
1.99%
Free cash flow per share (TTM)
205.88%
Growth
Revenue change (TTM)
19.36%
Earnings per share change (TTM)
15.23%
3-year revenue growth (CAGR)
13.01%
10-year revenue growth (CAGR)
9.17%
3-year earnings per share growth (CAGR)
37.32%
10-year earnings per share growth (CAGR)
21.71%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Bulls say / Bears say
Boston Scientific reported a 20.9% increase in net sales for Q1 2025, reaching $4.663 billion, surpassing expectations and indicating strong market demand. (stocktitan.net)
The company raised its full-year 2025 guidance, projecting 12%-14% organic growth, reflecting confidence in sustained performance. (seekingalpha.com)
Analysts have boosted their forecasts for Boston Scientific following its upbeat Q1 2025 results, with price targets raised by firms like Baird and RBC Capital. (benzinga.com)
Boston Scientific's rapid stock appreciation, nearly 40% over the past year, may limit near-term upside as many positives are already priced in. (seekingalpha.com)
The company faces challenges from unfavorable currency movements, with a 10 basis-point impact on revenues in Q3 2024, potentially affecting profitability. (nasdaq.com)
Macroeconomic pressures, including geopolitical tensions and supply chain disruptions, could create a challenging business environment for Boston Scientific. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 24 Jun 2025.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
BSX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Boston Scientific stock?
Boston Scientific (BSX) has a market cap of $153B as of July 04, 2025.
What is the P/E ratio for Boston Scientific stock?
The price to earnings (P/E) ratio for Boston Scientific (BSX) stock is 75.62 as of July 04, 2025.
Does Boston Scientific stock pay dividends?
No, Boston Scientific (BSX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Boston Scientific dividend payment date?
Boston Scientific (BSX) stock does not pay dividends to its shareholders.
What is the beta indicator for Boston Scientific?
Boston Scientific (BSX) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.